Summary: The current standard of care for patients with multiple myeloma is high dose chemotherapy and an autologous stem cell transplant. Although an autologous transplant is not a cure, maintenance therapy with various drugs can control myeloma in many patients for several years.
Panelists:
Jens Hillengass MD, Chief of Myeloma, Roswell Park Comprehensive Cancer Center. Meet Dr. Hillengass: [ Ссылка ]
Elizabeth O'Donnell MD, Director of Lifestyle Medicine and Medical Oncologist in the Multiple Myeloma Disease Center, Massachusetts General Hospital. Meet Dr. O'Donnell: [ Ссылка ]
Muthalagu Ramanathan MD, Medical Co-Director, Blood and Marrow Transplant Program, UMass Memorial Medical Center. Meet Dr. Ramanathan: [ Ссылка ]
To read the full transcript: [ Ссылка ]
Highlights:
- Anyone with multiple myeloma up to age 80, who is otherwise in good health and can tolerate chemotherapy, is a potential candidate for an autologous stem cell transplant.
- Having a second autologous transplant is a common treatment strategy. The period of remission after a second autologous transplant is usually less than that obtained after the first autologous transplant.
- A new strategy for treating patients with multiple myeloma that is showing great promise is CAR T-cell therapy.
July 16, 2020 Part of the Virtual Celebrating a Second Chance at Life Survivorship Symposium 2020. 59 minutes Question & Answer Session
Key Points:
03:46 A secondary cancer sometimes occurs in patients treated for multiple myeloma. The cause of these secondary cancers is not clear.
10:32 CT, MRIs and PET scans are all used to monitor myeloma lesions but provide different types of information that can help guide treatment decisions.
13:23 CAR T-cell therapy has been tested on patients with multiple myeloma with encouraging results.
15:41 The safety and effectiveness of an allogeneic transplant (transplant using donor cells) after an autologous transplant is still being researched.
19:48 The cytogenetics of multiple myeloma can change over time which can affect treatment decisions.
25:32 Some therapies used to treat patients with multiple myeloma can cause peripheral neuropathy.
34:40 Some myeloma patients experience “chemobrain” or changes in cognitive abilities as a result of treatment.
42:44 Multiple myeloma and therapies to treat it can cause changes in body composition such as weight loss and change in muscle mass. Remaining active and maintaining physical fitness are important during treatment.
52:29 Amyloidosis can co-exist with multiple myeloma. Treatment is similar to that for myeloma patients.
WHO WE ARE: BMT InfoNet is dedicated to providing patients and their loved ones with emotional support and high quality, easy-to-understand information about blood stem cell transplants (bone marrow, peripheral blood and cord blood) and other cellular therapies. Whether you are just beginning your transplant or cellular therapy journey, or learning to manage the joys and challenges of survivorship,
BMT InfoNet is here to help before, during and after treatment. Our goal is to empower you with credible information and emotional support, so that you can take a more active role in decisions affecting your health. [ Ссылка ]
VISIT US ON SOCIAL MEDIA:
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]
